| Date | Title | Description |
| 04.04.2025 | Imfinzi approved in EU for AEGEAN | Imfinzi approved in EU for AEGEAN
Fri, Apr 04, 2025 08:05 CET Report this content
04 April 2025
Imfinzi-based perioperative regimen approved in the EU for resectable non-small cell lung cancer
Approval based on AEGEAN Phase III trial result... |
| 20.03.2025 | European Markets Shudder as Wall Street Sells Off and Turkish Turmoil Unfolds | European markets are feeling the tremors of Wall Street's recent sell-off. On March 19, 2025, the pan-European STOXX 600 index dipped by 0.1%, following a rough day for U.S. stocks. Investors are on edge, grappling with fears of a slowdown ... |
| 17.03.2025 | Imfinzi approved in EU for limited-stage SCLC | Imfinzi approved in EU for limited-stage SCLC
Mon, Mar 17, 2025 08:05 CET Report this content
17 March 2025
Imfinzi approved in the EU as first and only immunotherapy
for limited-stage small cell lung cancer
Approval based on ADRIATIC Phase... |
| 08.03.2025 | Imfinzi's Breakthrough in Cancer Treatment: A New Dawn for Patients | In the world of oncology, every breakthrough feels like a ray of hope piercing through the clouds of despair. AstraZeneca's Imfinzi (durvalumab) is emerging as a beacon for patients battling early-stage gastric and non-small cell lung cance... |
| 03.03.2025 | Imfinzi recommended for EU approval for AEGEAN | Imfinzi recommended for EU approval for AEGEAN
Mon, Mar 03, 2025 08:00 CET Report this content
3 March 2025
Imfinzi-based perioperative regimen recommended for approval
in the EU by CHMP for resectable non-small cell lung cancer
Recommendat... |
| 03.02.2025 | Imfinzi recommended for EU approval for LS-SCLC | Imfinzi recommended for EU approval for LS-SCLC
Mon, Feb 03, 2025 08:00 CET Report this content
3 February 2025
Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung cancer
Reco... |
| 05.12.2024 | Imfinzi approved in US for limited-stage SCLC | Imfinzi approved in US for limited-stage SCLC
Thu, Dec 05, 2024 08:00 CET Report this content
5 December 2024
Imfinzi approved in the US as first and only immunotherapy
regimen for patients with limited-stage small cell lung cancer
Based on... |
| 16.08.2024 | Imfinzi approved in US for resectable lung cancer | Imfinzi approved in US for resectable lung cancer
Fri, Aug 16, 2024 08:00 CET Report this content
16 August 2024
Imfinzi approved in the US for the treatment of resectable
non-small cell lung cancer before and after surgery
Based on AEGEAN ... |
| 26.07.2024 | ODAC reviewed Imfinzi in resectable lung cancer | ODAC reviewed Imfinzi in resectable lung cancer
Fri, Jul 26, 2024 08:00 CET Report this content
26 July 2024
FDA Advisory Committee reviewed Imfinzi for treatment of resectable non-small cell lung cancer based on AEGEAN Phase III trial resu... |
| 02.07.2024 | Biomarker Testing: Improving Treatment for Metastatic Breast Cancer | Sorry, but your browser does not support the video tag.
(BPT) - Metastatic breast cancer (MBC), or stage IV breast cancer, is when the cancer has spread beyond the breasts to other parts of the body. While currently considered incurable, fo... |
| 25.06.2024 | Update on Imfinzi ADJUVANT BR.31 trial | Update on Imfinzi ADJUVANT BR.31 trial
Tue, Jun 25, 2024 08:05 CET Report this content
25 June 2024
Update on ADJUVANT BR.31 Phase III trial
of Imfinzi in non-small cell lung cancer
High-level results from the ADJUVANT BR.31 Phase III trial... |
| 05.04.2024 | Imfinzi improved OS & PFS in limited-stage SCLC | Imfinzi improved OS & PFS in limited-stage SCLC
Fri, Apr 05, 2024 08:00 CET Report this content
05 April 2024
Imfinzi significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung ... |
| 19.02.2024 | Tagrisso improved PFS in Stage III lung cancer | Tagrisso improved PFS in Stage III lung cancer
Mon, Feb 19, 2024 08:00 CET Report this content
19 February 2024
Tagrisso demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA ... |
| 14.11.2023 | Update on PACIFIC-2 Phase III trial for Imfinzi | Update on PACIFIC-2 Phase III trial for Imfinzi
Tue, Nov 14, 2023 08:05 CET Report this content
14 November 2023
Update on PACIFIC-2 Phase III trial of Imfinzi concurrently administered with platinum-based chemoradiotherapy in unresectable,... |
| 02.11.2023 | アストラゼネカ、肺がん啓発プロジェクト「知ってもらいたい、肺がんのこと。」河村隆一さんによる初の完全オリジナル楽曲「何気ないその笑顔が...」11月2日(木)公開... | アストラゼネカ株式会社（本社：大阪市北区、代表取締役社長：堀井 貴史、以下、アストラゼネカ）は11月の肺がん啓発月間における取り組みの一環として、肺がん治療経験のあるアーティスト河村隆一さんが、ご自身の経験や肺がん患者さんの声をもとに制作した、完全オリジナル応援ソング「何気ないその笑顔が...」をプロジェクト公式サイト（https://www.haigan-tomoni.jp/haigan_kenshin/project_k/）にて11月2日（木）より公開します。また、楽曲制... |
| 09.03.2023 | Imfinzi improved EFS in resectable lung cancer | Imfinzi improved EFS in resectable lung cancer
Thu, Mar 09, 2023 08:00 CET Report this content
9 March 2023 07:00 GMT
Imfinzi significantly improved event-free survival in AEGEAN
Phase III trial for patients with resectable non-small cell l... |
| 16.02.2023 | Q/A: Oatmeal Health Co-Founder Talks AI-Enabled Cancer Screening for the Underserved | Dr. Ty Vachon, CEO & Co-Founder at Oatmeal Health
Today, cancer is the second leading cause of death in the United States. Sadly, cancer disparities exist, with racial/ethnic minority, low-income, and uninsured populations suffering the... |
| 11.11.2022 | Imfinzi + Imjudo approved in US for lung cancer | Imfinzi + Imjudo approved in US for lung cancer
Fri, Nov 11, 2022 08:00 CET Report this content
11 November 2022 07:00 GMT
Imfinzi and Imjudo with chemotherapy approved in the US
for patients with metastatic non-small cell lung cancer
Appro... |
| 01.11.2022 | Nation’s Top Cancer Organizations Partner to Endorse Initiative to Increase Lung Cancer Screening in the United States | Some of the 50-plus organizations that signed onto a consensus statement urging national action to get more people screened for lung cancer. We estimate as many as 60,000 lives could be saved each year if the 14.5 million Americans who are ... |
| 30.06.2022 | Imfinzi improved pCR in resectable lung cancer | Imfinzi improved pCR in resectable lung cancer
Thu, Jun 30, 2022 08:00 CET Report this content
30 June 2022 07:00 BST
Imfinzi plus chemotherapy significantly improved pathologic complete response in AEGEAN Phase III trial in resectable non-... |
| 03.12.2021 | Exact Sciences : Going the Extra Mile | Going the Extra Mile
This year, our team turned out on foot and on bike at races across the United States (and beyond) to support cancer survivors and raise awareness. Along the way, many shared the personal "why" that inspires th... |
| 29.10.2021 | Sound Up for Lung Cancer | It's time to change the conversation. Patient inspired and community led, Sound Up aims to empower people affected by lung cancer in raising the volume to vocally self-advocate.
Oct 29, 2021
Overcoming challenges of living with lung cancer
... |
| 17.09.2021 | Innate Pharma : Monalizumab Data from COAST Trial Presented at ESMO Congress 2021 (Form 6-K) | Monalizumab Data from COAST Trial Presented at ESMO Congress 2021
MARSEILLE, France, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ('Innate' or the 'Company') today announced that AstraZeneca (LSE/S... |
| 17.09.2021 | Innate Pharma : Monalizumab Data from COAST Trial Presented at ESMO Congress 2021 | MARSEILLE, France, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented results from the randomized COAST Phase ... |
| 16.09.2021 | Drs. Erik Knelson, Dwight Owen, and Erin Schenk receive 10th annual LUNGevity Career Development Awards | |
| 16.09.2021 | Drs. Anil Vachani and Claudio Scafoglio Awarded LUNGevity Foundation 2021 Early Detection Awards | |
| 13.09.2021 | LUNGevity awards inaugural Health Equity and Inclusiveness Lung Cancer Research Awards | |
| 13.09.2021 | Drs. Michael Green, Jennifer Lewis, Manali Patel, and Harold Bien receive first-ever LUNGevity VA Research Scholar Awards | |
| 08.09.2021 | Raymond U. Osarogiagbon, MBBS, FACP, named LUNGevity Foundation's Community Champion honoree | |
| 02.09.2021 | New Education Initiative Seeks to Improve Clinical Trial Access and Education for Underserved Communities | Through this collaboration, we are able to reach patients, caregivers, nurses, and physicians to raise awareness about the critical need to increase diversity in cancer clinical trials so that all cancer patients benefit equally from advanc... |
| 23.08.2021 | LUNGevity Foundation and Partner RETpositive Issue 2022 Request for Applications for RET-Positive Translational Lung Cancer Research | |
| 23.08.2021 | LUNGevity Foundation and Partner Hamoui Family Foundation Issue 2022 Request for Applications for RET-Positive Clinical Lung Cancer Research | |
| 19.07.2021 | Imfinzi approved in China for extensive-stage SCLC | Imfinzi approved in China for extensive-stage SCLC Mon, Jul 19, 2021 08:00 CET
19 July 2021 07:00 BST
Imfinzi approved in China for the treatment
of extensive-stage small cell lung cancer
Only PD-1/PD-L1 immunotherapy to demonstrate both a ... |
| 30.06.2021 | Amgen : AtlanticLIVE and Amgen Highlight Inequities in Lung Cancer and the Importance of Biomarker Testing | An Amgen-sponsored panel at a recent AtlanticLIVE Equity of Cancer Care event explored biomarker testing access and racial disparities in lung cancer care.
Juanita Segura, Lung Cancer Patient and Advocate - Juanita is not being treated with... |
| 28.06.2021 | LUNGevity Foundation Names NFN Scout, MA, PhD, as Community Champions Honoree | |
| 05.05.2021 | LUNGevity Foundation Issues Request for Applications for New Health Equity for Communities Research Award | |
| 26.04.2021 | LUNGevity Welcomes Kristi M. Griffith, MSN, RN, CHPN, HON ONN-CG | |
| 26.04.2021 | LUNGevity Foundation Welcomes Arif J. Vega, PhD, as Director of Equity, Diversity, & Inclusion - Engagement and Outreach | |
| 20.04.2021 | LUNGevity Launches Campaign Focused on Increasing Lung Cancer Survival by Driving Awareness of Comprehensive Biomarker Testing | |
| 29.03.2021 | LUNGevity Welcomes Amy C. Moore, PhD, as Vice President of Global Engagement and Patient Partnerships | |
| 18.03.2021 | LUNGevity and Family Reach Announce New Partnership to Help Lung Cancer Patients Financially Plan for their Care | |
| 10.03.2021 | LUNGevity Announces Two Virtual Survivorship Conferences to Help People Live Well with Lung Cancer | |
| 08.03.2021 | LUNGevity Foundation Launches Health Equity Council | |
| 19.02.2021 | EGFR Resisters and LUNGevity Foundation Partner on Lung Cancer Research Award | |
| 05.02.2021 | LUNGevity Foundation Issues 2021 Requests for Applications for Two New Early-Stage Lung Cancer Research Awards Supporting Minority Investigators | |
| 05.02.2021 | LUNGevity Foundation Issues Request for Applications for 2021 Career Development Awards in Lung Cancer Translational Research | |
| 05.02.2021 | LUNGevity Foundation Issues 2021 Request for Applications for New Lung Cancer Translational Research Award Supporting Veterans Affairs Researchers | |
| 05.02.2021 | LUNGevity Foundation Issues Request for Applications for a 2021 Early Detection Award in Lung Cancer Translational Research | |
| 04.11.2020 | LUNGevity Foundation Launches Inhale for Life: Right Track Public Service and Social Media Campaign During Lung Cancer Awareness Month | |
| 28.10.2020 | LUNGevity Welcomes Bellinda King-Kallimanis, PhD, as Director of Patient-Focused Research | |
| 27.10.2020 | LUNGevity Foundation Welcomes Michael Kolodziej, MD, to Its Board of Directors | |
| 23.10.2020 | LUNGevity Launches New Lung Cancer Advocacy Program | |
| 29.09.2020 | Report shows insurance coverage of biomarker testing has not kept up with innovation | |
| 23.09.2020 | Lung Cancer Research Awards funded by ALK Positive Patient Group in Second Collaboration with LUNGevity Foundation | |
| 22.09.2020 | Maximilian Diehn, MD, PhD, joins LUNGevity's Scientific Advisory Board | |
| 11.09.2020 | Drs. Kathryn Arbour, Carl Gay, and Sean Pitroda receive prestigious LUNGevity 2020 Career Development Awards | |
| 27.08.2020 | LUNGevity Launches Lung Cancer Patient Research Project in Collaboration with the FDA | |
| 13.08.2020 | LUNGevity Foundation Welcomes Dr. Elizabeth Barksdale as New Director of Regulatory Affairs & Scientific Policy | |
| 06.10.2017 | A snapshot of personalized medicine in practice | But there are barriers that still need clearing, not only in Cannon’s group but also across the healthcare industry, when it comes to increasing access to personalized medicine. Namely, the costs, the gaps in knowledge of some providers who... |
| - | A cancer patient reconsiders her end-of-life wishes, as Covid-19 brings mortality into sharper focus | Even before she knew what kind of cancer she had, Robin Hodges knew she didn’t want to be resuscitated. If her heart and lungs began sputtering out, doctors should let them. Back in 1999, she’d watched her older sister die agitated and mutt... |
| - | A snapshot of personalized medicine in practice | From left: Mark Fleury, of American Cancer Society Cancer Action Network (moderator); Dr. Timothy Cannon of Inova Medical Group; Dr. Rasika Kalamegham, of Genentech; and Andrea Ferris of the LUNGevity Foundation.
Every Friday at noon in Fai... |
| - | Precision medicine: from targeted therapies to advancing outcomes in lung cancer | Over the past decade, precision medicine has garnered significant attention from the oncology community. By delivering therapies to patients most likely to benefit, precision medicine approaches have dramatically improved the outlook for pa... |
